Back to top
more

Cara Therapeutics (CARA)

(Delayed Data from NSDQ)

$9.01 USD

9.01
375,753

+0.34 (3.92%)

Updated Sep 28, 2022 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.63%
2Buy18.00%
3Hold9.55%
4Sell5.25%
5Strong Sell2.32%
S&P50010.82%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 251)

Industry: Medical - Biomedical and Genetics

Trades from $1

Zacks News

Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Cara Therapeutics (CARA) Ahead of Earnings?

Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 0% and 6.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

UnitedHealth (UNH) to Post Q1 Earnings: What to Expect

UnitedHealth Group's (UNH) first-quarter results are likely to reflect the benefits of improving premiums and products.

Cara Therapeutics (CARA) Reports Q4 Loss, Lags Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of -26% and 77.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q4

Bayer (BAYRY) beats estimates for both earnings and revenues in the fourth quarter of 2021.

Earnings Preview: Cara Therapeutics (CARA) Q4 Earnings Expected to Decline

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium

Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of first-quarter 2022.

Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA

Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.

Charles River (CRL) to Report Q4 Earnings: What's in Store?

The acquisitions of Vigene Biosciences and Cognate are likely to have a full-quarter favorable impact on Charles River's (CRL) Q4 Manufacturing Support revenues.

Illumina (ILMN) Q4 Earnings and Revenues Beat Estimates

Illumina (ILMN) delivered earnings and revenue surprises of 50% and 0.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases fourth-quarter 2021 results.

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates, especially its lead candidate CTX001.

Regeneron (REGN) Q4 Earnings and Revenues Top Estimates

Regeneron (REGN) delivered earnings and revenue surprises of 28.29% and 7.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) to Report Q4 Earnings: What's in the Cards?

LabCorp's (LH) Covance Drug Development Q4 results are expected to reflect an increase in organic revenues on base business growth and contribution from COVID testing performed through the central lab.

CVS Health (CVS) Q4 Earnings to Gain From COVID Vaccine Sales

CVS Health (CVS) is expected to have seen a significant part of its specialty orders being placed digitally through Q4 months, with growth drivers being COVID testing, vaccines and omni-channel.

Dr. Reddy's (RDY) Q3 Earnings, Sales Increase Year Over Year

Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.

Regeneron (REGN) Withdraws sBLA for Libtayo in Cervical Cancer

Regeneron (REGN) and partner Sanofi voluntarily withdraw the supplemental biologics license application for Libtayo in second-line treatment of advanced cervical cancer.

BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study

BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.

ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC

The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.

Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?

Zimmer Biomet (ZBH) struggles to sustain the recovery trend in the second half of 2021.

What's in Store for Quest Diagnostics (DGX) in Q4 Earnings?

In Q4, Quest Diagnostics' (DGX) non-COVID base business might have registered a year-over-year sales rebound.

Vertex (VRTX) Q4 Earnings & Sales Beat, '22 View Upbeat

Vertex Pharmaceuticals' (VRTX) earnings and sales surpass estimates for the fourth quarter of 2021. The company provides its revenue guidance for 2022.

What's in Store for Boston Scientific's (BSX) Q4 Earnings?

On a geographic basis, every Boston Scientific (BSX) market in fourth-quarter 2021 is expected to have registered broad-based growth compared with the dull fourth-quarter 2020 numbers.